TNDM · XBRL financial data

Tandem Diabetes Care financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (TNDM's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue from contracts with customers	186	197	192	222	244	283	234	241	249	290	247	255
Cost of goods and services sold	96	104*	97	109	119	125*	116	115	115	123*	110	110
Gross profit	90	93	95	113	125	157	118	126	134	167	137	145
Selling, general and administrative	79	86*	90	94	100	106*	114	110	108	113*	108	112
Total operating expenses	121	128	136	144	151	158	239	178	157	159	154	159
Operating income (loss)	(32)	(35)	(42)	(31)	(26)	(1)	(121)	(52)	(23)	8	(17)	(14)
Interest expense	5	2*	2	2	2	2*	2	2	2	2*	2	2
Other income (expense)	1	4*	2	1	3	1*	(1)	(6)	(2)	(4)*	(2)	(7)
Income tax expense (benefit)	2	(1)*	3	1	1	(1)*	8	(5)	(4)	5*	1	1
Net income (loss)	(33)	(30)	(43)	(31)	(23)	1	(131)	(52)	(21)	(1)	(20)	(21)
Earnings per share, basic USD per share	(0.51)	(0.46)	(0.65)	(0.47)	(0.35)	0.01	(1.97)	(0.78)	(0.31)	(0.01)	(0.30)	(0.31)
Earnings per share, diluted USD per share	(0.51)	(0.46)	(0.65)	(0.47)	(0.35)	0.01	(1.97)	(0.78)	(0.31)	(0.01)	(0.30)	(0.31)
Weighted average shares, basic millions of shares	65	65	65	65	66	66	66	67	68	68	68	69
Weighted average shares, diluted millions of shares	65	65	65	65	66	66	66	67	68	68	68	69

Fiscal quarters (TNDM's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	80	59	59	48	49	69	54	64	92	91	179	63
Short-term investments	419	409	409	405	424	369	315	251	227	202	391	393
Accounts receivable	100	106	93	98	107	115	127	128	126	165	141	162
Inventory	143	158	154	162	152	150	141	143	137	129	126	135
Prepaid and other current assets	16	17	21	21	20	22	27	28	35	31	50	51
Total current assets	758	748	735	733	753	724	663	615	617	618	887	805
Property and equipment, net	76	77	78	79	81	78	79	78	78	84	83	85
Right-of-use asset	89	88	88	88	87	85	101	98	98	96	96	100
Total assets	940	953	941	938	958	968	922	876	875	881	1,153	1,154
Accounts payable	46	50	48	48	49	45	60	56	47	47	60	64
Accrued liabilities	14	13	11	13	12	18	14	14	13	21	19	26
Current portion of long-term debt	—	0	—	41	41	41	—	—	—	—	—	—
Total current liabilities	187	195	193	241	259	247	288	252	253	243	248	253
Long-term debt	—	285	—	307	308	308	309	309	310	310	602	603
Lease liability, non-current	116	114	113	111	109	106	123	120	118	115	113	116
Total liabilities	626	639	698	704	720	705	767	742	742	726	1,021	1,024
Accumulated deficit	(922)	(952)	(995)	(1,025)	(1,049)	(1,048)	(1,178)	(1,231)	(1,252)	(1,253)	(1,273)	(1,294)
Total stockholders' equity	314	314	243	234	238	263	155	133	133	155	132	130
Total liabilities and equity	940	953	941	938	958	968	922	876	875	881	1,153	1,154
Common shares outstanding (cover page) millions of shares	65	66	65	65	66	66	67	68	68	68	69	70

Fiscal quarters (TNDM's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(33)	(30)	(43)	(31)	(23)	1	(131)	(52)	(21)	(1)	(20)	(21)
Stock-based compensation	21*	23*	22	25*	26*	28*	25	26*	21*	20*	16	16*
Depreciation and amortization	4*	4*	4	4*	4*	4*	4	4*	4*	4*	5	4*
Net cash from operating activities	0*	(7)*	(8)	(5)*	27*	11*	(18)	(9)*	8*	10*	11	(35)*
Purchases of property and equipment	5*	5*	4	6*	5*	3*	3	6*	4*	7*	6	4*
Net cash from investing activities	(49)*	(17)*	(5)	(4)*	(20)*	5*	9	58*	21*	(15)*	(195)	(87)*
Proceeds from issuing common stock	(2)*	3*	(2)	(3)*	(5)*	2*	—	—	—	—	—	—
Share repurchases	—	year only	30	0*	0*	0*	0	0*	0*	0*	—	—
Net cash from financing activities	(2)*	3*	14	(3)*	(5)*	2*	(5)	(40)*	(2)*	3*	274	2*
Net change in cash	(51)*	(21)*	0	(11)*	1*	20*	(16)	11*	28*	(1)*	89	(117)*

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Tandem Diabetes Care	63	255	(35)*	69.6M	13.2 quarters	Q2 FY26 10-QJun 30, 2026
Alphatec Holdings	80	221	19*	155.1M	—	Q3 FY26 10-QSep 30, 2026
Artivion	77	126	(1.3)*	48.8M	61.1 quarters	Q2 FY26 10-QJun 30, 2026
CONMED	48	336	49*	29.8M	—	Q3 FY26 10-QSep 30, 2026
AtriCure	168	154	22*	50.9M	—	Q2 FY26 10-QJun 30, 2026
NovoCure	97	193	23	116.9M	—	Q3 FY26 10-QSep 30, 2026
Lemaitre Vascular	27	not reported	16*	22.9M	—	Q2 FY26 10-QJun 30, 2026
Establishment Labs Holdings	71	68	(17)*	29.8M	4.3 quarters	Q2 FY26 10-QJun 30, 2026
Ufp Technologies	9	174	16*	7.7M	—	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.